DNA methylation status at diagnosis in MDS predicts response to azacitidine
Journal of Clinical Investigation · 2026-11-16 · 136 (22)
DOI: 10.1172/jci208317 ↗At a glance
Klinische Studie in Journal of Clinical Investigation, published on 2026-11-16. Written by Qin Yang and 16 co-authors. Institution: Department of Biochemistry & Molecular Biology, and. Major MEDLINE topics: DNA Methylation, Myelodysplastic Syndromes, Azacitidine, Epigenesis, Genetic. The full text is freely available (open access, CC BY 4.0). Funded by: NCI NIH HHS, NHLBI NIH HHS, Blood Cancer United.
Abstract (original language)
BACKGROUND Myelodysplastic syndromes (MDS) are characterized by aberrant DNA methylation, and mutations in epigenetic modifiers are frequently found in these patients. Although DNA methyltransferase inhibitors are used to treat MDS, response variability remains a challenge in the clinic, with limited predictive markers. METHODS We integrated genomic, epigenomic, and transcriptomic analyses of n = 98 patients with MDS. Patients were classified into epigenetic subtypes via hierarchical clustering. Random forest classifiers were developed and validated using internal stratified testing and an independent external cohort to predict azacitidine (AZA) response. RESULTS MDS are characterized by widespread DNA hypomethylation affecting distal regulatory elements. We identified 7 epigenetic clusters correlated with distinct molecular drivers. Notably, cluster VI exhibited low mutational burden but a high AZA response rate of 71% ( P ≤ 0.01). While transcriptional profiles alone failed to distinguish responders, a DNA methylation–based (DNAme-based) classifier achieved an area under the curve (AUC) of 0.82. An integrative model combining DNAme, gene expression, mutations, and clinical parameters achieved an AUC of 0.93 in internal validation and 0.88 in the external cohort. CONCLUSION Epigenetic signatures at distal genomic elements provide superior predictive power for AZA response compared with promoter-centric or transcriptional analyses. These findings establish a robust framework for personalized treatment strategies in MDS. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT01522976. FUNDING NIH National Heart, Lung, and Blood Institute grant: R01HL126947; Leukemia and Lymphoma Society: grants 13-5719, 7028-22.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Biochemistry & Molecular Biology, and.
- Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA.
- MDS Unit, Hematology, DMSC University of Florence, AOU Careggi, Florence, Italy.
- Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.
- Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.
- Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine, Baltimore, Maryland, USA.
Funding
- NCI NIH HHS
- NHLBI NIH HHS
- Blood Cancer United
- NHLBI
Cite
APA
Yang, Q., Torres-Martin, M., Taguchi, M., Brogi, A., Casalin, I., Ceneri, E., Halene, S., DeZern, A. E., Griffiths, E. A., Follo, M. Y., Finelli, C., Radich, J. P., Rauh, M. J., Bejar, R., Sekeres, M. A., Santini, V., & Figueroa, M. E. (2026). DNA methylation status at diagnosis in MDS predicts response to azacitidine. Journal of Clinical Investigation. https://doi.org/10.1172/jci208317
Vancouver
Yang Q, Torres-Martin M, Taguchi M, Brogi A, Casalin I, Ceneri E, et al. DNA methylation status at diagnosis in MDS predicts response to azacitidine. Journal of Clinical Investigation. 2026. doi:10.1172/jci208317
BibTeX
@article{Yang2026,
author = {Yang, Qin and Torres-Martin, Miguel and Taguchi, Masataka and Brogi, Alice and Casalin, Irene and Ceneri, Eleonora and Halene, Stephanie and DeZern, Amy E and Griffiths, Elizabeth A and Follo, Matilde Y and Finelli, Carlo and Radich, Jerald P and Rauh, Michael J and Bejar, Rafael and Sekeres, Mikkael A and Santini, Valeria and Figueroa, Maria E},
title = {DNA methylation status at diagnosis in MDS predicts response to azacitidine},
journal = {Journal of Clinical Investigation},
year = {2026},
doi = {10.1172/jci208317}
}
EUVIMED